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Background and purpose: Preoperative 5-fluorouracil-based chemoradiotherapy is a standard treatment
for locally advanced lower rectal cancer (LALRC). We performed a phase I study to develop a new regimen
combining irinotecan and S-1.
Materials and methods: Patients with LALRC (T3-4, N0-2) were studied. The radiation dose was 45 Gy in
25 fractions. S-1 (80 mg/m2/day) was administered on days 1–5, 8–12, 22–26, and 29–33. Irinotecan was
administered on days 1, 8, 22, and 29. The dose of irinotecan was initially 60 mg/m2 (level 1). Surgery was
performed 6–10 weeks after the chemoradiotherapy.
Results: Twenty patients were enrolled, of whom 18 patients were analyzed. Dose-limiting toxicity (DLT)
did not occur in the first 3 patients treated with irinotecan at 80 mg/m2 (level 2), but developed in 3 of the
6 patients who received irinotecan at 90 mg/m2 (level 3). Then DLT occurred in 3 other patients at level 2.
At level 2 or 3, DLT comprised neutropenia, thrombocytopenia, and diarrhea. Level 2 was designated as
the maximum tolerated dose, and level 1 as a recommended dose (RD). The pathological complete
response rate was 28%, and the down-staging rate was 56%.
Conclusions: Our results suggested that the RD of irinotecan when combined with preoperative S-1 and
pelvic radiation was 60 mg/m2.
 2016 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 120 (2016) 222–227.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Many studies have evaluated the effectiveness of preoperative
chemo/radiotherapy in patients with locally advanced rectal can-
cer because it potentially offers advantages such as tumor shrink-
age, lower toxicity than postoperative radiotherapy, and a higher
sphincter preserving rate [1]. In a prospective randomized trial
from the German Rectal Cancer Study Group, fluorouracil-based
preoperative chemoradiotherapy showed improved local control
rate and reduced treatment-related toxicities in compared with
postoperative chemoradiotherapy for clinical stage II/III rectal can-
cer, although OS were similar results in both groups [2]. Thus, theNational Comprehensive Cancer Network Clinical Practice Guideli-
nes in Oncology recommend 5-fluorouracil (5-FU)-based preoper-
ative chemoradiotherapy as a standard treatment option for
patients with rectal cancer who have T3, N0 disease, any T, N1-2
disease, or T4 disease [3].
Recently, several randomized controlled trials have been con-
ducted to evaluate the effect of adding oxaliplatin to 5-FU-based
regimens for preoperative chemoradiotherapy. However, oxali-
platin has been reported to increase toxicity. Some studies
reported that oxaliplatin did not improve tumor response [4,5],
whereas others reported that oxaliplatin improved tumor response
[6] and disease-free survival [7]. The development of new regimens
for preoperative chemoradiotherapy is thus needed to further
enhance treatment response.
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tegafur, a prodrug of 5-FU, with gimeracil and oteracil potassium
in a molar ratio of 1:0.4:1. Gimeracil is dihydropyrimidine dehy-
drogenase (DPD) inhibitor that acts to maintain high levels of 5-
FU in plasma and has been suggested to have radiosensitizing
activity [8,9]. Oteracil potassium decreases gastrointestinal toxic-
ity caused by 5-FU.
As for combined chemotherapy with S-1 plus irinotecan (IRIS), a
randomized controlled trial (FIRIS study) showed that IRIS is non-
inferior to a combination of fluorouracil, folinic acid, and irinotecan
(FOLFIRI) in terms of progression-free survival time as second-line
therapy for unresectable colorectal cancer [10]. IRIS is expected to
become a useful regimen for the management of unresectable col-
orectal cancer because of several potential benefits, including a
shorter infusion time and fewer hospital visits.
In a phase II trial performed by Sato et al., chemoradiotherapy
with S-1 plus irinotecan had a histopathological complete response
(pCR) rate of 34.7% in patients with locally advanced rectal cancer
[11]. However, the clinical target volume for the primary tumor
used typically included the perirectal lymph nodes. The target vol-
umes used for radiotherapy in that study were much smaller than
those generally used in North American and European practice, in
which the internal iliac nodes and often the external iliac nodes
were electively irradiated.
To further evaluate the safety and effectiveness of preoperative
chemoradiotherapy with S-1 plus irinotecan, we extended the irra-
diated field to the standard range and performed a multicenter
phase I study in patients with locally advanced lower rectal cancer
(SAMRAI-1). Our primary purpose was to determine the RD of
irinotecan. We also studied whether extension of the radiation
field leads to increased toxicity (particularly gastrointestinal
toxicity).Methods and materials
Eligibility criteria
Eligible patients had to satisfy all of the following criteria: (1) a
histologically confirmed diagnosis of rectal cancer (adenocarci-
noma); (2) resectable clinical stage T3 or T4, N0-2 disease with
the primary tumor located either above or below the peritoneal
reflection, the inferior tumor margin located distally to the peri-
toneal reflection, and no enlarged nodules measuring P10 mm in
diameter suggesting extramesorectal metastasis on computed
tomography (slice width, 65 mm) (i.e., no distinct metastasis to
lateral lymph nodes), as confirmed by imaging studies performed
within 4 weeks before enrollment; (3) no hepatic, peritoneal, or
distant metastasis; (4) an age of 20–80 years at enrollment; (5)
no previous treatment; and (6) no severe compromise of main
organ functions, with a white cell count of 4000/lL or more and
less than 12,000/lL, a platelet count of 100  103/lL or more, a
hemoglobin level of 9.0 g/dL or more, a total bilirubin level of
1.5 mg/dL or less, aspartate aminotransferase and alanine amino-
transferase levels of less than twice the institutional upper limit
of normal, a serum creatinine level of less than the institutional
upper limit of normal, and an creatinine clearance rate of
50 mL/min or more. Patients also had to have ECOG performance
status of 0 or 1 and to be able to orally receive drugs. Written
informed consent was obtained from all patients before
enrollment.Exclusion criteria
Patients were excluded from the study if they had any of the fol-
lowing conditions: a history of serious drug hypersensitivity;
active double cancer or multiple colorectal cancers; a genotypeof UGT1A1*6/*6, UGT1A1*28/*28, or were heterozygous for both
(UGT1A1*6/*28); active infection (fever of 38.0 C or higher); seri-
ous complications (e.g., intestinal paralysis or intestinal obstruc-
tion); a history of interstitial pneumonia; diarrhea (watery stool);
or positive test results for HBs antigen. In patients with a genotype
of UGT1A1*6/*6 or UGT1A1*28/*28 or who were heterozygous for
both UGT1A1*6/*28, treatment with irinotecan has been reported
to possibly cause serious adverse events, especially neutropenia
[12]. Therefore, patients with these genotypes were excluded from
the present study.
Treatment
Radiotherapy
Radiotherapy was delivered with 10 MV X-rays in 1.8 Gy daily
standard fractionation for a total dose of 45 Gy. Fig. 1 shows the
target volume.
(1) Gross tumor volume
The gross tumor volume included the primary tumor, enlarged
lymph nodes, and suspected sites of tumor invasion of adjacent
organs. The primary lesion was evaluated on barium enema exami-
nation and MRI. To maintain consistency with the results of a study
bySato et al. [11], an enlarged lymphnodewith adiameter of 1 cmor
morewasdefinedasnodalmetastasis in accordancewithRECIST1.0.
(2) Clinical target volume
The clinical target volume was derived by adding a 1 cmmargin
to the gross tumor volume and included the mesorectal lymph
nodes (pararectal lymph nodes), internal iliac lymph nodes, and
the obturator lymph nodes.
(3) Planning target volume
The planning target volume was derived by adding a margin of 1
cm to the clinical target volume. The superior margin of the typical
irradiation field was defined as the level between the fifth lumbar
and first sacral vertebrae. The inferior margin was 3 to 4 cm below
the inferior edge of the primary lesion, as defined by a line to the infe-
rior margin of the ischial tuberosity, in principle. Irradiation of the
skin of the anal region was avoided as much as possible. The lateral
margins were 1 cm lateral to the cavity of the lesser pelvis. The ante-
riormarginwas the posteriormargin of the pubic symphysis, and the
posteriormarginwas the center of the sacral bone on the lateral view.
Completely different subgroups might be intermingled among
patients who have enlarged lateral lymph nodes 1 cm or more in
diameter. In the present study, we therefore studied patients with
no lateral lymph node metastasis and did not perform prophylactic
lymph-node dissection, which is commonly done in Japan. Because
radiotherapy was given preoperatively, the same radiation dose
was delivered to the planned target volume (PTV) in all patients.
The dose was prescribed to the beam isocenter or near to this
point with tissue inhomogeneity correction for dose calculation.
No tissue inhomogeneity correction was performed if there was
too much air in the rectum.
To decrease the intestinal volume included in the treated field,
the prone position was recommended for irradiation. To minimize
exposure of the small intestine to radiation, the use of a belly board
device was recommended, although fixation of body position was
not required.
Chemotherapy
The dose of S-1 was determined according to body surface area
(BSA) as follows: BSA <1.25 m2, 80 mg/day; BSA P1.25 m2 to
The superior margin is 
the rectosigmoid 
junction
The inferior margin is the level at which the levator ani 
muscle enters the intestinal wall. 
The adipose tissue surrounding the levator ani muscle 
only in patients with invasion of the levator ani muscle.
If the fascia of the rectal muscularis 
propria is visualized on CT, seen clearly 
on T2-weighted MRI. 
Example of primary site delineation Sagittal  Coronal
Fig. 1. An example of primary site delineation.
224 NCRT with S-1 plus irinotecan for LALRC<1.5 m2, 100 mg/day; and BSAP1.5 m2, 120 mg/day. S-1 was given
orally twice daily after breakfast and dinner for 5 days followed by
a 2-day rest, on days 1–5, 8–12, 22–26, and 29–33. Irinotecan was
given as a continuous intravenous infusion on days 1, 8, 22, and 29.
The first 3 patients received irinotecan in a dose of 60 mg/m2 (level
1). The dose was increased in a stepwise fashion 80 mg/m2 (level
2), 90 mg/m2 (level 3), and 100 mg/m2 (level 4) until the maximum
tolerated dose (MTD) was reached. If level 1 met the conditions for
the MTD, the dose was reduced to 40 mg/m2 (level 0).Operation
Surgery was performed at least 6 weeks after the completion of
radiotherapy. Patients underwent abdominoperineal resection
(APR) or lower anterior resection (LAR). A temporary ileostomy
was created in patients who underwent LAR. Total mesorectal exci-
sion was performed. Lateral lymph-node dissection was not per-
formed unless distinct metastasis to the lateral lymph nodes was
confirmed on imaging studies after completion of the protocol
treatment (immediately before surgery) or intraoperatively.Dose-limiting toxicity (DLT)
Adverse events were evaluated according to the Common Ter-
minology Criteria for Adverse Events, version 3.0. DLT was defined
as any of the following events or conditions occurring within
28 days after the completion of chemoradiotherapy: grade 4 hema-
tologic toxicity; grade 3 neutropenia associated with a fever of
P38 C; grade 3 or higher thrombocytopenia, grade 3 or higher
nonhematologic toxicity (excluding anorexia nausea, and vomit-
ing); the dose of S-1 was decreased or S-1 was given for 13 days
or less because of adverse events; treatment with irinotecan was
skipped on days 8, 22, and 29 or the dose of irinotecan was reduced
because of adverse events; chemotherapy scheduled for day 22 had
to be postponed for 1 week or longer because of adverse events; orradiotherapy had to be discontinued for 1 week or longer because
of adverse events.Dose-escalation scheme
The MTD was defined as the dose level that produced DLT in at
least 3 of 6 patients. If DLT occurred in 1 or 2 of the first 3 patients,
3 additional patients were assigned to receive the same dose level.
If none of the first 3 patients receiving a given dose level had DLT or
if 1 or 2 of 6 patients had DLT, the dose was increased to the next
level. Dose escalation was not allowed in the same patient. The
dose level immediately below the MTD was considered the recom-
mended dose (RD) for Phase II studies.Assessment
The primary endpoint of the study was to estimate the MTD and
RD of irinotecan. Secondary endpoints were safety (incidences of
adverse events and complications), the curative resection (R0) rate,
down-staging rate, and pathological complete response (pCR) rate.
The antitumor effects of preoperative chemoradiotherapy were
evaluated according to the tumor-node-metastasis classification
[13], and the down-staging rate was calculated. Baseline evalua-
tions were performed on imaging studies before the start of
chemoradiotherapy. Tumor response was evaluated immediately
before surgery at least 4 weeks after the completion of chemora-
diotherapy. The histopathological response was also evaluated. In
patients with measurable tumors, histological response was
graded according to the ‘‘General Rules for Clinical and Pathologi-
cal Studies on Cancer of the Colon, Rectum and Anus (7th Edition),
and the results were included in evaluation of the effectiveness of
preoperative chemoradiotherapy [14]. These evaluations were per-
formed in each participating hospital. Adverse events were evalu-
ated according to the Common Terminology Criteria for Adverse
Events, version 3.0.
Table 1
Patient characteristics.
Variable Total (N = 18) Level 1 (N = 6) Level 2 (N = 6) Level 3 (N = 6)
Age
Median 58 54 60.5 57.5
Range [34–77] [42–66] [47–77] [34–71]
Sex
Male 15 6 4 5
Female 3 0 2 1
ECOG PS
0 17 5 6 6
1 1 1 0 0
Tumor site
Rab 5 1 4 0
Rba 4 2 0 2
Rb 9 3 2 4
Stage
II A 7 4 0 3
III B 10 2 5 3
IIIC 1 0 1 0
Abbreviations: Ra denotes the rectum above the peritoneal reflection; Rb, the rectum below the peritoneal reflection; Rab, the rectum above and below peritoneal reflection;
and Rba, the rectum below and above peritoneal reflection.
Table 2
Dose-limiting toxicity.
Patient
No.
Level No. of patients
with DLT
Type of
DLT*
Adverse events
1-1 1 2/6 (3) Diarrhea
1-3 (4–6) Diarrhea, Leukopenia,
Neutropenia
2-4 2 3/6 (1,2,4,5) Neutropenia, Leukopenia,
Thrombocytopenia
2-5 (3,7) Radiation-associated
pneumonitis
2-6 (4,5) Leukopenia, Neutropenia
3-2 3 3/6 5) Neutropenia
3-5 (4–6) Leukopenia, Neutropenia
3-6 (3–5) Diarrhea, Abdominal pain
(1) A fever of 38 C or higher accompanied by grade 3 neutropenia.
(2) Grade 3 or higher thrombocytopenia.
(3) Grade 3 or higher nonhematologic toxicity (excluding anorexia and nausea/
vomiting),
(4) If the dose of S-1 was decreased or the number of days of treatment was less
than two thirds of that required by the protocol because of adverse events (i.e.,
13 days or less).
(5) If treatment with irinotecan on days 8, 22, or 29 was skipped or the dose was
decreased because of adverse events.
(6) If the resumption of chemotherapy on day 22 had to be delayed for 1 week or
longer because of adverse events.
(7) If irradiation had to be discontinued for 1 week or longer because of adverse
events.
* Types of DLT (Definition)
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ment to death from any cause or the last follow-up, and relapse-
free survival (RFS) was defined as the time from enrollment to
recurrence or death. Overall survival and RFS were estimated by
using Kaplan–Meier method.
The present study was conducted in accordance with the ethical
principles of the Declaration of Helsinki and the Japanese ‘‘Ethical
Guidelines for Clinical Study” to maximally ensure the human
rights, welfare, and safety of the subjects. Written informed con-
sent was obtained from all patients. The protocol was approved
by the relevant institutional review boards or ethics committees
at each center after a careful review of the ethical and scientific
aspects of the study.Results
From February 2009 through December 2011, a total of 20
patients were enrolled at 7 hospitals. Two patients violated the cri-
teria for dosage and treatment with the study drugs. The other 18
patients were included in data analysis. The clinical characteristics
of the patients are shown in Table 1. The subjects ranged in age
from 34 to 77 years and comprised 15 men and 3 women. The per-
formance status was 0 in 17 patients and 1 in 1.
Table 2 summarizes the DLT according to dose level. At level 1
(irinotecan 60 mg/m2), the first patient and third patient had DLT,
and 3 additional patients were studied. In total, DLT developed in 2
of the 6 patients, and the dose level was increased to level 2
(irinotecan 80 mg/m2). None of the first 3 patients who received
level 2 (irinotecan 60 mg/m2) had DLT, and the dose was increased
to level 3 (irinotecan 90 mg/m2). At level 3, DLT developed in the
second patient, and 3 patients were additionally studied. In total,
3 of 6 the patients who received level 3 had DLT.
Rules for the dose-escalation scheme: If DLT occurred in at least
3 of 6 patients at a given dose, that dose level was defined as the
MTD. According to this definition, dose level 3 was the MTD. How-
ever, after the dose was increased from level 1 to level 2, only 3
patients had received level 2. Therefore, 3 additional patients were
given level 2. All 3 of these patients had DLT at level 2, and level 2,
at which DLT developed in 3 of the 6 patients, was designated as
the MTD, and dose level 1 was the RD.
Adverse events developing between the start of treatment and
day 28 after the completion of chemoradiotherapy were evaluated
(Table 3). Grade 3 or higher adverse events were leukopenia in 3
patients (16.7%), neutropenia in 3 (16.7%), thrombocytopenia in 1
(5.6%), anorexia in 1 (5.6%), and diarrhea in 2 (11.1%). At level 1,
the only grade 3 or higher adverse event was diarrhea in 1 patient.
At level 2, diarrhea occurred in 2 patients. No patients had grade 3
diarrhea. At level 3, diarrhea occurred in 3 patients. One patient
had grade 3 diarrhea. There were no grade 4 adverse events.
Postoperative complications were liver dysfunction in 1 patient
at level 1 and bleeding, acute intestinal ischemia, perineal wound
infection, and intestinal obstruction in 1 patient each at level 3.
The patient with acute intestinal ischemia subsequently reported
to have died of treatment-related causes.
The antitumor effectiveness of preoperative chemoradiotherapy
was evaluated in all 18 patients. Down-staging was observed in
Table 3
Adverse events.
Adverse events (CTCAE, ver. 3.0) Total (N = 18) Level 1 (N = 6) Level 2 (N = 6) Level 3 (N = 6)
Any Grade G3 Any Grade G3 Any Grade G3 Any Grade G3
Laboratory findings
Leukopenia 17 3 6 5 2 6 1
Neutropenia 7 3 2 2 2 3 1
Thrombocytopenia 6 1 2 2 1 2
Hemoglobin 3 1 2
Total bilirubin 3 3
Creatinine 1 1
AST (GOT) 2 1 1
ALT (GPT) 2 1 1
Clinical findings
Anorexia 4 1 1 2 1 1
Radiation-associated dermatitis 2 2
Diarrhea 8 2 3 1 2 3 1
Nausea 2 1 1
Vomiting 2 1 1
Fatigue 2 2
Stomatitis/pharyngitis 1 1
Anal pain 5 3 1 1
Hyperpigmentation 1 1
Hiccoughs 1 1
Alopecia 1 1
226 NCRT with S-1 plus irinotecan for LALRC10 patients (55.6%). Down-staging of T stage was confirmed in 9
patients (50%) and down-staging of N stage in 7 (38.9%). The pCR
rate was 27.8%, and the R0 rate was 100% (Table 4).
Fig. 2 shows the OS and RFS. As of June 2015, 3 patients (16.7%)
died, among whom 2 patients died of recurrence of primary cancer,
and 1 died of sepsis and necrosis of the small intestine. Six patients
(33.3%) had metastases to the lung (5 patients, 27.8%) or distant
lymph nodes (1 patient, 5.6%). After a median follow-up of
54.4 months, the 3-year and 5-year OS rates were both 82.6%,
and the 3-year and 5-year RFS rates were 70.8% and 57.2%,
respectively.Fig. 2. Overall survival (solid line) and relapse-free survival (dotted line).
Discussion
In this phase I study of preoperative chemoradiotherapy with S-
1 and irinotecan, the RD of irinotecan was determined to be 60 mg/
m2 in patients with locally advanced lower rectal cancer. In
patients with a genotype of UGT1A1*6/*6 or UGT1A1*28/*28 orTable 4
Tumor response.
PatientsNo. Level Before treatment ? After t
1-1 1 T3N1M0 T2N0M
1-2 1 T3N0M0 T3N0M
1-3 1 T3N0M0 T3N1M
1-4 1 T3N1M0 T3N0M
1-5 1 T3N0M0 T0N0M
1-6 1 T3N0M0 T2N0M
2-1 2 T4N1M0 T3N1M
2-2 2 T3N1M0 T0N0M
2-3 2 T3N1M0 T3N2M
2-4 2 T3N1M0 T3N0M
2-5 2 T3N1M0 T0N0M
2-6 2 T4N2M0 T2N0M
3-1 3 T3N0M0 T3N1M
3-2 3 T3N1M0 T3N2M
3-3 3 T3N1M0 T4N2M
3-4 3 T3N1M0 T0N0M
3-5 3 T3N0M0 T3N0M
3-6 3 T3N0M0 T0N0Mwho were heterozygous for both UGT1A1*6/*28, treatment with
irinotecan has been reported to possibly cause serious adverse
events, especially neutropenia. Therefore, patients with thesereatment Down Stage pCR (Grade 3) R0 resection
0 U U
0 U
0 U
0 U U
0 U U U
0 U U
0 U
0 U U U
0 U
0 U U
0 U U U
0 U U
0 U
0 U
0 U
0 U U U
0 U
0 U U U
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of irinotecan was determined, caution is required for characteristic
adverse events, such as neutropenia and diarrhea. Several clinical
trials of chemoradiotherapy with S-1 and irinotecan have been per-
formed in Japan and Korea. A phase I/II study performed by Shin
et al. obtained a pCR rate of 21.0% with a regimen combining
70 mg/m2/day of S-1 with 40 mg/m2 of weekly irinotecan [15]. In
a single center phase I/II study, Sato et al. obtained a pCR rate of
34.7% with a regimen of 80 mg/m2/day of S-1 plus 80 mg/m2 of
irinotecan with same schedule as this study [8]. Furthermore, the
5-year local recurrence-free survival rates were 93% [16]. We
obtained a pCR rate of 27.8%, which was consistent with the results
of previous studies. On the other hand, in the chemoradiotherapy
with fluoropyrimidine and oxaliplatin studies, pCR rate was about
20%, and observed increased toxicity with addition of oxaliplatin
[17,18].
This was a multicenter phase I study of patients who were
enrolled at 7 institutions. To prevent differences in radiotherapy
among hospitals, a radiotherapy committee was established to
clearly define the radiation fields and doses before the study began.
The radiotherapy committee was responsible for quality control
and quality assurance, ensuring that radiotherapy was adminis-
tered according to the study protocol. We thereby confirmed that
there were no protocol violations, despite minor differences among
the participating centers. We confirmed that there were no major
differences in the radiation methods or fields between patients
with DLT and those without DLT. The relation between radiother-
apy and the occurrence of DLT in individual patients appeared to
be weak. Although there was only a weak relation of radiotherapy
to DLT, our radiation field was larger than that used in the single-
center study performed by Sato et al., potentially increasing toxic-
ity at level 2 of irinotecan (80 mg/m2). The larger radiation field
might have led to the lower RD of irinotecan (60 mg/m2) as com-
pared with that in single-center studies. In the study by Sato
et al. (10), the dose of irinotecan was 80 mg/m2, and all grades of
diarrhea occurred in 7 (10.4%) of the 67 patients. Grade 3 or higher
diarrhea occurred in 3 patients (4.5%). In this study, at level 2 (dose
irinotecan, 80 mg/m2), all grades of diarrhea occurred in 2 (33.3%)
of the 6 patients, and no patient had grade 3 or higher diarrhea. We
could not conclude that the size of the irradiation field influenced
the incidence of diarrhea.
The chemoradiotherapy with S-1 and irinotecan was generally
tolerable, and the pCR rate was promising. At present, a phase II
study of chemoradiotherapy with S-1 plus irinotecan at the RD of
60 mg/m2 is ongoing to better define the radiation field
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